{"disease":{"id":"neurofibromatosis-1","name":"neurofibromatosis 1"},"drugs":{"marketed":[{"drug_id":"selumetinib","indication_name":"Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06379230","title":"A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT00026780","title":"Eligibility Screening for a NCI Pediatric Oncology Branch Research Study","phase":"","overall_status":"COMPLETED","enrollment_count":1720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT07327164","title":"Precision Medicine for Neurocutaneous Syndromes in Western China","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT04941027","title":"Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1","phase":"","overall_status":"COMPLETED","enrollment_count":1046,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT05954416","title":"FARD (RaDiCo Cohort) (RaDiCo-FARD)","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT06523582","title":"Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Universidad Nacional Autonoma de Mexico","has_results":false},{"nct_id":"NCT03757247","title":"Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation","phase":"","overall_status":"UNKNOWN","enrollment_count":670,"lead_sponsor_name":"Medical University Innsbruck","has_results":false},{"nct_id":"NCT00684398","title":"Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I","phase":"","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT04463316","title":"GROWing Up With Rare GENEtic Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"dr. Laura C. G. de Graaff-Herder","has_results":false},{"nct_id":"NCT01445314","title":"Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments","phase":"","overall_status":"COMPLETED","enrollment_count":598,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05581511","title":"Natural History Study of Cutaneous Neurofibromas in People With NF1","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT02544022","title":"Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)","phase":"","overall_status":"RECRUITING","enrollment_count":476,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00111384","title":"Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)","phase":"","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04774289","title":"Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)","phase":"","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00924196","title":"Natural History Study of Patients With Neurofibromatosis Type I","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":259,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03406208","title":"Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing","phase":"NA","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06222203","title":"Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)","phase":"","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01089101","title":"Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":217,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06360406","title":"Real-World Treatment Study of Koselugo (Selumetinib)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07221331","title":"Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06188741","title":"Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT05005845","title":"NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"NFlection Therapeutics, Inc.","has_results":true},{"nct_id":"NCT05913037","title":"FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":167,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT03871257","title":"A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":165,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03975829","title":"Pediatric Long-Term Follow-up and Rollover Study","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":163,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04954001","title":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT04924608","title":"Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05388370","title":"PASS of Paediatric Patients Initiating Selumetinib","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":124,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04561765","title":"Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Yale University","has_results":true},{"nct_id":"NCT03962543","title":"MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":114,"lead_sponsor_name":"SpringWorks Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06880991","title":"Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study","phase":"","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01362803","title":"AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":99,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05677594","title":"Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT01553149","title":"Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05735717","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT05331105","title":"HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Shanghai Kechow Pharma, Inc.","has_results":false},{"nct_id":"NCT06507748","title":"A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05361811","title":"Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02471339","title":"Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07024394","title":"Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":65,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT04212351","title":"Frameshift Peptides of Children With NF1","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT05149469","title":"Molecular Aspects of Preimplantation Genetic Diagnosis for NF1","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT04201457","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":false},{"nct_id":"NCT04750928","title":"Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07521657","title":"Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT05912400","title":"Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1","phase":"","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"University of Arkansas","has_results":true},{"nct_id":"NCT05196854","title":"Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1","phase":"NA","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Murdoch Childrens Research Institute","has_results":false},{"nct_id":"NCT04879160","title":"Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial","phase":"","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01125046","title":"Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Northwestern University","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}